These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25670009)

  • 1. Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.
    Pendzialek JB; Danner M; Simic D; Stock S
    Health Policy; 2015 May; 119(5):654-63. PubMed ID: 25670009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consumer price sensitivity in Dutch health insurance.
    van Dijk M; Pomp M; Douven R; Laske-Aldershof T; Schut E; de Boer W; de Boo A
    Int J Health Care Finance Econ; 2008 Dec; 8(4):225-44. PubMed ID: 18709549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Market Concentration in the Statutory Health Insurance of Germany since the Introduction of Free Choice of Sickness Funds].
    Götze R
    Gesundheitswesen; 2016 Nov; 78(11):715-720. PubMed ID: 25760099
    [No Abstract]   [Full Text] [Related]  

  • 4. Consumer price sensitivity and social health insurer choice in Germany and The Netherlands.
    Schut FT; Gress S; Wasem J
    Int J Health Care Finance Econ; 2003 Jun; 3(2):117-38. PubMed ID: 14626009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching gains and health plan price elasticities: 20 years of managed competition reforms in The Netherlands.
    Douven R; Katona K; T Schut F; Shestalova V
    Eur J Health Econ; 2017 Nov; 18(8):1047-1064. PubMed ID: 28243775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The German Central Health Fund-recent developments in health care financing in Germany.
    Göpffarth D; Henke KD
    Health Policy; 2013 Mar; 109(3):246-52. PubMed ID: 23200602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managed competition and consumer price sensitivity in social health insurance.
    Schut FT; Hassink WH
    J Health Econ; 2002 Nov; 21(6):1009-29. PubMed ID: 12475123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free choice of sickness funds: economic implications and ethical aspects of the 1992 health care reform in Germany.
    Cassel D; Boroch W
    J Med Philos; 1995 Dec; 20(6):657-67. PubMed ID: 8861572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Competition among health insurance funds: the position of the PKV].
    Leienbach V
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(10):639-42; discussion 643. PubMed ID: 20120193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in price elasticities of demand for health insurance: a systematic review.
    Pendzialek JB; Simic D; Stock S
    Eur J Health Econ; 2016 Jan; 17(1):5-21. PubMed ID: 25398619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care reform: managed competition and beyond.
    Custer W
    EBRI Issue Brief; 1993 Mar; (135):1-33. PubMed ID: 10129612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. German risk structure compensation: enhancing equity and effectiveness.
    Files A; Murray M
    Inquiry; 1995; 32(3):300-9. PubMed ID: 7591043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing health care market reform through an insurance exchange: essential policy components, the public plan option, and other issues to consider.
    Fronstin P; Ross MN
    EBRI Issue Brief; 2009 Jun; (330):1-22. PubMed ID: 19545086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition.
    Busse R; Blümel M; Knieps F; Bärnighausen T
    Lancet; 2017 Aug; 390(10097):882-897. PubMed ID: 28684025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the sickness funds in the Belgian health care market.
    Nonneman W; van Doorslaer E
    Soc Sci Med; 1994 Nov; 39(10):1483-95. PubMed ID: 7863360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market competition in health care markets in the Netherlands: some lessons for England?
    den Exter AP; Guy MJ
    Med Law Rev; 2014; 22(2):255-73. PubMed ID: 24841530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elasticities of market shares and social health insurance choice in Germany: a dynamic panel data approach.
    Tamm M; Tauchmann H; Wasem J; Gress S
    Health Econ; 2007 Mar; 16(3):243-56. PubMed ID: 16981190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forming and reforming the market for third-party purchasing of health care: a German perspective.
    Graf von der Schulenburg JM
    Soc Sci Med; 1994 Nov; 39(10):1473-81. PubMed ID: 7863359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [External and internal financing in health care].
    Henke KD
    Med Klin (Munich); 2007 May; 102(5):366-72. PubMed ID: 17497087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.